📷 Image: Wikimedia Commons / Ministry of Health and Family Welfare
Health
CDSCO Orders Sun Pharma to Stop Eye-Care Drug Production Over Quality Lapses
✍️ Business Standard
🗓 30 Oct 2026, 07:46 PM
👁 12
The Central Drugs Standard Control Organization has directed Sun Pharmaceutical Industries to halt the manufacture of its eye-care medicines after discovering significant quality issues.
The Central Drugs Standard Control Organization (CDSCO) has issued a directive to Sun Pharmaceutical Industries to immediately cease production of its eye-care drugs.
The order follows a series of quality control lapses identified during routine inspections, including deviations in active ingredient concentrations and contamination risks.
Health authorities warn that the affected products could pose safety risks to patients, prompting the halt to prevent potential harm.
Sun Pharma has acknowledged the directive and is cooperating with regulators to investigate the root causes and resume production once compliance is restored.
The order follows a series of quality control lapses identified during routine inspections, including deviations in active ingredient concentrations and contamination risks.
Health authorities warn that the affected products could pose safety risks to patients, prompting the halt to prevent potential harm.
Sun Pharma has acknowledged the directive and is cooperating with regulators to investigate the root causes and resume production once compliance is restored.